A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 that may be altered by sorafenib including the perc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Monk, Paul, Lam, Elaine, Mortazavi, Amir, Kendra, Kari, Lesinski, Gregory B., Mace, Thomas A., Geyer, Susan, Carson, William E., Tahiri, Sanaa, Bhinder, Arvinder, Clinton, Steven K., Olencki, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2014
Assuntos:
Clinical Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3966917/
https://ncbi.nlm.nih.gov/pubmed/24598448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados